Nanotechnology Meets Traditional Medicine: Emerging Strategies to Improve Wound Healing Outcomes

Key Takeaways

• Nanocarrier systems significantly enhance the stability, bioavailability, and skin penetration of Traditional Chinese Medicine (TCM)-derived compounds, addressing longstanding translational barriers.
• TCM bioactives exhibit multi-target activity—simultaneously modulating infection, inflammation, oxidative stress, angiogenesis, and tissue remodeling—making them well suited for complex chronic wounds.
• Despite promising preclinical results, challenges in safety evaluation, standardization, and large-scale manufacturing continue to limit clinical translation.

Chronic wounds remain a persistent clinical challenge, particularly in conditions such as diabetes and vascular disease, where prolonged inflammation, infection, and impaired angiogenesis disrupt the normal sequence of tissue repair. A recent review in Pharmaceutics synthesizes emerging evidence on how nanotechnology-enabled delivery systems may unlock the therapeutic potential of bioactive compounds derived from Traditional Chinese Medicine (TCM), offering a multi-target approach to wound healing .

The pathophysiology of chronic wounds is increasingly understood as a self-sustaining network of dysregulated processes. Persistent microbial biofilms, excessive reactive oxygen species (ROS), and an imbalance in inflammatory signaling collectively prevent progression from the inflammatory to proliferative phase of healing. In this context, TCM-derived compounds—ranging from flavonoids like baicalin and quercetin to saponins such as ginsenosides—demonstrate broad pharmacologic activity across multiple pathways. These agents can disrupt biofilms, suppress pro-inflammatory cytokines, scavenge ROS, and promote angiogenesis and extracellular matrix remodeling, reflecting a systems-level therapeutic profile .

Yet, their clinical utility has historically been constrained by pharmacokinetic limitations. Many of these compounds exhibit poor aqueous solubility, low stability, and limited transdermal penetration. Nanotechnology-based delivery systems are now being explored to overcome these barriers. Liposomes, polymeric nanoparticles, nanogels, and inorganic nanomaterials can encapsulate bioactive compounds, improving their solubility and protecting them from degradation while enabling controlled and localized release at the wound site .

Importantly, these delivery platforms are not merely passive carriers. Advances in stimuli-responsive systems allow drug release to be triggered by specific features of the wound microenvironment, such as acidic pH, elevated protease activity, or increased ROS levels. For example, pH-sensitive nanoparticles can preferentially release antimicrobial agents in infected, acidic wound beds, while ROS-responsive systems simultaneously reduce oxidative stress and deliver anti-inflammatory compounds. This “sense-and-respond” paradigm represents a shift toward precision therapeutics tailored to the dynamic biology of chronic wounds .

Preclinical studies highlighted in the review demonstrate encouraging outcomes. Nanostructured lipid carriers loaded with ginsenosides have been shown to enhance collagen deposition and angiogenesis in diabetic wound models, while mesoporous silica nanoparticles delivering quercetin improved both inflammatory control and re-epithelialization. Composite systems, such as nanoparticle-loaded hydrogels, further integrate physical wound protection with sustained drug delivery, illustrating the potential for multifunctional therapeutic platforms .

Despite these advances, significant hurdles remain. Most data derive from in vitro experiments or small animal models, which may not fully capture the complexity of human chronic wounds. Variability in TCM-derived compounds—stemming from differences in plant sources and extraction methods—poses challenges for reproducibility and regulatory standardization. Additionally, the long-term safety of certain nanomaterials, particularly inorganic systems, requires further investigation before widespread clinical adoption .

The authors emphasize that future progress will depend on integrating pharmacologic insight with materials science and clinical validation. Standardized manufacturing processes, well-defined quality attributes, and robust safety data will be essential to move these therapies from bench to bedside.

As the burden of chronic wounds continues to grow globally, the convergence of traditional pharmacology and nanotechnology offers a compelling avenue for innovation. While still in early stages, these hybrid strategies may ultimately reshape how clinicians approach complex wound care—shifting from single-target interventions to coordinated, multi-mechanistic therapies designed for the realities of impaired healing.